Global Janus Kinase (JAK) Inhibitors Market - 2024-2032

Global Janus Kinase (JAK) Inhibitors Market - 2024-2032

The global Janus Kinase (JAK) Inhibitors market reached US$ 13.23 billion in 2023 and is expected to reach US$ 29.76 Billion by 2032, growing at a CAGR of 8.4% during the forecast period 2024-2032.

Pipeline Drugs

Janus kinase is a group of proteins that are involved in the cytokine signaling pathway. These are known to play a crucial role in several autoimmune, allergic, and inflammatory conditions. There are notably four Janus kinase (JAK) proteins, named JAK1, JAK2, JAK3, and TYK2. These interact with seven signal transducers and activators of transcription (STAT) transcription factors to mediate intracellular signal transduction downstream of cytokine receptors.

Janus Kinase (JAK) inhibitors are drugs indicated in various conditions and are specifically known to inhibit the Janus kinase pathway. JAK1 is a key kinase involved in pruritic dermatitis, allergic rhinitis, asthma, and inflammatory bowel disease. Small-molecule inhibitors targeting JAK1 have shown efficacy in treating these diseases. Small molecules with JAK1 and JAK2 inhibitory activity have also provided therapeutic benefits in rheumatoid arthritis, psoriasis, and pruritis. JAK3 selective inhibitors and JAK1/TYK2 dual inhibitors have potential therapeutic options in inflammatory and autoimmune diseases.

The market for Janus Kinase (JAK) inhibitors is expected to see lucrative growth in the future driven by factors such as increasing efforts by manufacturers to discover, develop, and commercialize novel drugs, rising prevalence of targeted diseases, and increasing demand for novel therapies.

Market Dynamics: Drivers & Restraints

Rising product development activities and market approvals

The market for janus kinase (JAK) inhibitors is expected to be significantly driven by rising product development activities and subsequent market approvals. Established manufacturers and emerging players are actively involved in developing novel JAK inhibitors and also extensively conducting clinical trials to explore new indications for the approved JAK inhibitors.

For instance, in 2023, the U.S. Food and Drug Administration (FDA) approved Ojjaara, a JAK inhibitor developed by GSK Plc, for the treatment of myelofibrosis patients. Omjjaara was then approved in the EU and UK in January 2024 for the same indication.

Moreover, in April 2023, the European Commission (EC) approved Rinvoq a JAK inhibitor developed by AbbVie for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF). Subsequently, in May 2023, the U.S. FDA approved Rinvoq for the same indication.

This increasing product launch is expected to create significant traction in various therapeutic areas with high unmet needs and propel the overall market growth.

The side effects associated with Janus Kinase (JAK) inhibitors may restrain the market growth.

Janus kinase (JAK) inhibitors, although revolutionizing the treatment scenario for several immunity-related conditions, are associated with certain risks and side effects. The serious side effects of JAK inhibitors include increased risk for infections, cardiovascular events (stroke, embolism, thrombosis, etc), and neoplasms.

A study published in The Nature Journal Scientific Reports in May 2022, has evaluated the adverse events associated with the first three approved JAK inhibitors: ruxolitinib, tofacitinib, and baricitinib. The sutdy evaluated 126,815 reports from the WHO pharmacovigilance database, and the most common adverse events reported are
• Increased incidence of infectious disease, especially viral infections such as herpes, influenza, fungal infections, and mycobacterial infectious disorders.
• Musculoskeletal and connective tissue disorders
• Cardiovascular events such as thrombosis and embolism
• Cancers especially malignant skin neoplasms.

The adverse effects are life-threatening and can impair the patient's outcome. This can lead to a decreased adoption rate and may impair market growth.

For more details on this report – Request for Sample

Segment Analysis

The global Janus Kinase (JAK) Inhibitors market is segmented based on Product, mechanism, indication, and region.

Upadacitinib is growing with the highest CAGR in the product segment of the Janus Kinase (JAK) Inhibitors market.

Upadacitinib sold under the brand name Rinvoq is a JAK inhibitor approved for the treatment of multiple indications including eczema, psoriatic arthritis, non-radigraphic axial spondyloarthritis, Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis etc. Among children, the drug is approved for active polyarticular juvenile idiopathic arthritis and active psoriatic arthritis. Rinovoq is manufactured by AbbVie and is available as a once-daily pill for all the above indications.

The drug is approved in major markets such as North America, European Union, and Japan for different indications.

Rinvoq sales are skyrocketing each year, majorly due to expanding applications, and geographic reach. AbbVie has generated US$ 47 million in the launch year 2019 and has generated US$ 3.97 billion in 2023, which is a growth of 203% in 4 years.

Moreover, AbbVie is expanding the clinical applications of Rinvoq by exploring its potential in newer indications. Rinvoq is being explored in phase 3 clinical trials for Alopecia Areata, Hidradenitis Suppurativa, Systemic Lupus Erythematosus (SLE), Takayasu Arteritis, and Vitiligo. This can further boost Rinvoq sales in the forecasted period.

Geographical Analysis

North America is expected to hold a significant share of the Janus Kinase (JAK) Inhibitors market.

North America currently holds a significant market share in the Janus Kinase (JAK) Inhibitors market due to various factors including, higher demand for novel therapies, major revenue generated by market players, and higher prevalence of autoimmune disorders. Any emerging drug is expected to first get launched in the U.S. market due to higher demand, and all the Janus Kinase (JAK) Inhibitors in the current market were first launched in the U.S., providing first access to the patients in the country. Due to higher per-capita income and spending on healthcare, the Janus Kinase (JAK) Inhibitors are sold at higher prices in the North America market as compared to other nations. Due to this, manufacturers generate a majority of their revenue from the region.

For instance, below are the top 5 selling Janus kinase (JAK) inhibitors and their revenue share by region. The top 5 selling drugs generated approximately US$ 11 billion in 2023, of which nearly 62% is from the U.S. This represents the dominance of the region in the global market.

Competitive Landscape

The major global players in the Janus Kinase (JAK) Inhibitors market are Eli Lilly and Company., Bristol Myers Squibb company., GSK Plc., Pfizer Inc., Incyte., AbbVie Inc., Astellas Pharma Inc, LEO Pharma A/S, Torii Pharmaceutical Co.,Ltd, and Sobi, Inc. among others.

Emerging Players

The emerging players in the Janus Kinase (JAK) Inhibitors market include Alfasigma Group, and Asana BioSciences, LLC., HIGHLIGHTLL PHARMA, Akeso Biopharma Co., Ltd. among others.

Key Developments
• In July 2024, the U.S. Food and Drug Administration approved LEQSELVI (deuruxolitinib) for treating adults with severe alopecia areata. LEQSELVI is an oral Janus Kinase (JAK) inhibitor developed by Sun Pharmaceutical Industries Limited and is available at a dose of 8mg tablets.
• In September 2023, the U.S. Food and Drug Administration approved OJJAARA (momelotinib) a Janus Kinase (JAK) inhibitor for treating myelofibrosis patients with anemia. Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor developed by GSK, and can treat anemia, constitutional symptoms, and splenomegaly in myelofibrosis patients.
• Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Janus Kinase (JAK) Inhibitors market report would provide approximately 68 tables, 65 figures, and 230 pages.

Target Audience 2023
• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.